Please login to the form below

Not currently logged in
Email:
Password:

NOAC

This page shows the latest NOAC news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Bad news for Portola as CHMP considers Factor Xa drugs

Portola Pharmaceuticals’ efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting

Latest news

  • Joerg Moeller to head Bayer R&D after operational shake-up Joerg Moeller to head Bayer R&D after operational shake-up

    It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase

  • BMS’ Opdivo defies naysayers with healthy growth BMS’ Opdivo defies naysayers with healthy growth

    Outside oncology, BMS’ top performer was novel oral anticoagulant Eliquis (apixaban), which grew 39% to $1.27bn, with Caforio claiming it is the most prescribed NOAC in the US, Japan and

  • Xarelto no better than aspirin in secondary stroke study Xarelto no better than aspirin in secondary stroke study

    The NOAC has 'very little' chance of showing overall benefit, says data monitoring committee. ... Bayer and Johnson &Johnson have abandoned a 7, 000-patient trial pitting their novel oral anticoagulant (NOAC) Xarelto against aspirin for ischaemic stroke

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    Overall J&J's group sales rose almost 2% to $18.9bn in the second quarter, with novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) rising 8% to $642m in the quarter and

  • Xarelto beats aspirin for recurrent blood clots Xarelto beats aspirin for recurrent blood clots

    The new trial results now show - for the first time - that a NOAC is even more effective. ... Meanwhile, the overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as

More from news
Approximately 11 fully matching, plus 20 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • NOAC Education: Empowering Stroke Prevention

    The use of oral anticoagulants in patients with atrial fibrillation. NOAC reversal agents. ... PCM Scientific is always open to additional sources of funding support to expand the educational offerings of the NOAC education site.

  • Cogora

    PCM Scientific, Cogora’s CME division, developed NOAC Education as an independent educational initiative with a single, central goal: to support clinicians in providing optimal anticoagulation care for patients at risk

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics